(1R,3S)-3-(tert-butyldimethylsilyloxy)cyclopentanol | 774232-87-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,3S)-3-(tert-butyldimethylsilyloxy)cyclopentanol
• 英文别名: (+)-(1R,3S)-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentanol；(1R,3S)-3-(tert-butyl-dimethyl-silanyloxy)-cyclopentanol；cis-3-[Tert-butyl(dimethyl)silyl]oxycyclopentanol；(1R,3S)-3-[tert-butyl(dimethyl)silyl]oxycyclopentan-1-ol
• CAS: 774232-87-0
• 化学式: C₁₁H₂₄O₂Si
• 分子量: 216.396
• InChiKey: NLXIOZRBFNUITF-ZJUUUORDSA-N

物化性质

• 沸点：
  245.3±33.0 °C(Predicted)
• 密度：
  0.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.92
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R,3S)-3-(tert-butyldimethylsilyloxy)cyclopentanol 在 二苯基膦叠氮化物 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 以70%的产率得到(+)-(1S,3S)-(3-azido-cyclopentyloxy)-tert-butyl-dimethylsilane
  参考文献：
  名称：

  Pyrimido compounds having antiproliferative activity

  摘要：

  公开了新型的嘧啶化合物，它们是对KDR和FGFR激酶的选择性抑制剂。这些化合物及其药用可接受的盐类是抗增殖剂，在治疗或控制实体瘤，特别是乳腺癌、结肠癌、肺癌和前列腺癌中是有用的。还公开了含有这些化合物的药物组合物和治疗癌症的方法。

  公开号：

  US20040204427A1
• 作为产物：
  描述：

  2-环戊烯-1-醇,4-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]-,(1S,4R)- 在 氢氧化钯 氢气 作用下， 以 乙酸乙酯 为溶剂， 25.0 ℃ 、13.51 MPa 条件下， 反应 16.0h， 以to give 2.0 g of the title compound (32)的产率得到(1R,3S)-3-(tert-butyldimethylsilyloxy)cyclopentanol
  参考文献：
  名称：

  Cycloalkylamine substituted isoquinolone derivatives

  摘要：

  本发明涉及式(I)的6-取代异喹啉衍生物，用于治疗和/或预防与Rho激酶和/或Rho激酶介导的肌球蛋白轻链磷酸酶磷酸化有关的疾病，以及含有这种化合物的组合物。

  公开号：

  US08742116B2

文献信息

• Scaffolding Catalysts: Highly Enantioselective Desymmetrization Reactions
  作者：Xixi Sun、Amanda D. Worthy、Kian L. Tan

  DOI：10.1002/anie.201103470

  日期：2011.8.22

  Ex‐changing places: A highly enantioselective desymmetrization of 1,2‐diols has been developed in which the catalyst utilizes reversible covalent bonding to the substrate to achieve both high selectivity and rate acceleration (see scheme, PMP=pentalmethylpiperidine, TBS=tert‐butyldimethylsilyl). Induced intramolecularity is responsible for the enhanced rate, thus allowing the reaction to be performed at

  交换位置：已开发出 1,2-二醇的高度对映选择性去对称化，其中催化剂利用与底物的可逆共价键来实现高选择性和速率加速（参见方案，PMP=五甲基哌啶，TBS=叔丁基二甲基甲硅烷基）。诱导的分子内性是提高速率的原因，因此可以在室温下进行反应。
• Enantioselective silyl protection of alcohols promoted by a combination of chiral and achiral Lewis basic catalysts
  作者：Nathan Manville、Hekla Alite、Fredrik Haeffner、Amir H. Hoveyda、Marc L. Snapper

  DOI：10.1038/nchem.1708

  日期：2013.9

  Catalytic enantioselective monosilylations of diols and polyols furnish valuable alcohol-containing molecules in high enantiomeric purity. These transformations, however, require high catalyst loadings (20–30 mol%) and long reaction times (2–5 days). Here, we report that a counterintuitive strategy involving the use of an achiral co-catalyst structurally similar to the chiral catalyst provides an effective solution to this problem. A combination of seemingly competitive Lewis basic molecules can function in concert such that one serves as an achiral nucleophilic promoter and the other performs as a chiral Brønsted base. On the addition of 7.5–20 mol% of a commercially available N-heterocycle (5-ethylthiotetrazole), reactions typically proceed within one hour, and deliver the desired products in high yields and enantiomeric ratios. In some instances, there is no reaction in the absence of the achiral base, yet the presence of the achiral co-catalyst gives rise to facile formation of products in high enantiomeric purity. A counter-intuitive strategy that combines a chiral Lewis base catalyst with an achiral Lewis base co-catalyst results in an exceptionally large increase in the facility of catalytic enantioselective silylation of polyols. The catalytic ensemble drives such reactions to completion within a few hours, rather than the usual two–five days, without loss of enantioselectivity.

  二元醇和多元醇的催化对映体选择性单硅烷化反应可以提供高对映体纯度的有价值含醇分子。然而，这些转化需要较高的催化剂负载量（20-30 摩尔%）和较长的反应时间（2-5 天）。在此，我们报告了一种反直觉策略，即使用结构上与手性催化剂相似的非手性辅助催化剂，从而有效地解决了这一问题。看似相互竞争的路易斯碱分子组合可以协同发挥作用，其中一个作为非手性亲核促进剂，另一个作为手性布氏碱。加入7.5â20Â mol%的市售N-杂环（5-乙基噻四唑）后，反应通常会在一小时内进行，并以较高的产率和对映体比率得到所需的产物。在某些情况下，如果没有非手性碱，则不会发生反应，但如果有非手性辅助催化剂存在，则很容易形成对映体纯度很高的产物。将手性路易斯碱催化剂与非手性路易斯碱助催化剂结合在一起的反直觉策略可显著提高多元醇的对映选择性硅烷化催化效率。这种催化组合可在几小时内完成此类反应，而不是通常的两天到五天，而且不会丧失对映选择性。
• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20070276138A1

  公开（公告）日：2007-11-29

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W. R 1 is —(CH 2 ) n —CH(OR 2 )—(CH 2 ) m E, —(CH)═C(OR 2 )—(CH 2 ) m E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or —(CH)═C(Y)—(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 -alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C 0-4 -alkyl; R 2 is —H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or —C(S)NR 5 R 6 . R 3 is —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is —O—, —CH 2 —, —CH 2 CH 2 — or —CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  公开了一种化合物，其结构式表示为（I）：其中Ar是取代或未取代的芳香族基团。Q是共价键，-CH2-或- -；W是取代或未取代的烷基或取代或未取代的异烷基连接基团，长度为两到十个原子，优选长度为两到七个原子。苯环A可以选择性地用最多四个取代基取代R1和W。R1是-( )n-CH(OR2)-( )mE，-(CH)=C(OR2)-( )mE，-( )n-CH(Y)-( )mE或-(CH)=C(Y)-( )mE；其中E是COOR3，C1-C3-烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，其中磺酰胺，酰基磺酰胺和四唑可以选择性地用一个或多个取代基取代，独立地选自C1-C6烷基，卤代烷基和芳基-C0-4-烷基；R2是-H，一种脂肪基，一种取代的脂肪基，卤代烷基，一种芳香基，一种取代的芳香基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或-C（S）NR5R6；R3是-H，一种脂肪基，一种取代的脂肪基，一种芳香基或一种取代的芳香基；Y是-O-，- -，- -或-CH═CH-，并与苯环A中与R1正交的碳原子键合；R4-R6独立地是-H，一种脂肪基，一种取代的脂肪基，一种芳香基或一种取代的芳香基；n和m独立地为0、1或2。
• CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES
  申请人：PLETTENBURG Oliver

  公开号：US20100056518A1

  公开（公告）日：2010-03-04

  The invention relates to 6-substituted isoquinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  本发明涉及公式（I）的6-取代异喹啉衍生物，用于治疗和/或预防与Rho-激酶和/或Rho-激酶介导的肌球蛋白轻链磷酸酶磷酸化相关的疾病，以及含有此类化合物的组合物。
• WO2008/77551
  申请人：——

  公开号：——

  公开（公告）日：——